Inspira Technologies Reports Over 95% Success in Infection Prevention
Ticker: IINNW · Form: 6-K · Filed: Feb 11, 2025 · CIK: 1837493
Sentiment: bullish
Topics: medical-devices, healthcare, clinical-results
TL;DR
Inspira Technologies hit >95% efficacy in preventing bloodstream infections, good news for patient safety.
AI Summary
On February 11, 2025, Inspira Technologies Oxy B.H.N. Ltd. announced positive results from its study on preventing bloodstream infections, achieving over 95% efficacy. The company furnished a press release as Exhibit 99.1 with its Form 6-K filing.
Why It Matters
This development could significantly reduce hospital-acquired infections, leading to better patient outcomes and lower healthcare costs.
Risk Assessment
Risk Level: medium — While positive, the results are from a study and further regulatory approvals and market adoption are needed.
Key Numbers
- 95% — Efficacy Rate (Achieved in preventing bloodstream infections)
Key Players & Entities
- Inspira Technologies Oxy B.H.N. Ltd. (company) — Registrant
- February 11, 2025 (date) — Filing date and announcement date
FAQ
What specific technology or product did Inspira Technologies use to achieve these results?
The filing does not specify the exact technology or product, only that it relates to preventing bloodstream infections.
What is the next step for Inspira Technologies following these positive results?
The filing indicates the results were announced via press release, but does not detail the next steps for regulatory approval or commercialization.
Were these results from a clinical trial, and if so, what was the scope?
The filing refers to 'positive results' and a press release titled 'Inspira Achieves Positive Results of Above 95% For Preventing Bloodstream Infections,' implying a study or trial, but specific details on its scope are not provided in this Form 6-K.
What is the Commission File Number for Inspira Technologies?
The Commission File Number for Inspira Technologies is 001-40303.
Where is Inspira Technologies headquartered?
Inspira Technologies is headquartered at 2 Ha-Tidhar St., Ra'anana 4366504, Israel.
Filing Stats: 307 words · 1 min read · ~1 pages · Grade level 8.8 · Accepted 2025-02-11 07:15:12
Filing Documents
- ea0230643-6k_inspira.htm (6-K) — 12KB
- ea023064301ex99-1_inspira.htm (EX-99.1) — 13KB
- ex99-1_001.jpg (GRAPHIC) — 9KB
- 0001213900-25-011925.txt ( ) — 38KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Inspira Technologies Oxy B.H.N. Ltd. Date: February 11, 2025 By: /s/ Dagi Ben-Noon Name: Dagi Ben-Noon Title: Chief Executive Officer 2